The Potential of Phosphorylated α-synuclein As a Biomarker for the Diagnosis and Monitoring of Multiple System Atrophy

Overview

Journal CNS Neurosci Ther

Specialties Neurology
Pharmacology

Date 2024 Apr 4

PMID 38572788

Authors

Toufik Abdul-Rahman

Ranferi Eduardo Herrera-Calderon

Arjun Ahluwalia

Andrew Awuah Wireko

Tomas Ferreira

Joecelyn Kirani Tan

Maximillian Wolfson

Shankhaneel Ghosh

Viktoriia Horbas

Vandana Garg

Asma Perveen

Marios Papadakis

Ghulam Md Ashraf

Athanasios Alexiou

Affiliations

Soon will be listed here.

Abstract

Introduction: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder characterized by the presence of glial cytoplasmic inclusions (GCIs) containing aggregated α-synuclein (α-Syn). Accurate diagnosis and monitoring of MSA present significant challenges, which can lead to potential misdiagnosis and inappropriate treatment. Biomarkers play a crucial role in improving the accuracy of MSA diagnosis, and phosphorylated α-synuclein (p-syn) has emerged as a promising biomarker for aiding in diagnosis and disease monitoring.

Methods: A literature search was conducted on PubMed, Scopus, and Google Scholar using specific keywords and MeSH terms without imposing a time limit. Inclusion criteria comprised various study designs including experimental studies, case-control studies, and cohort studies published only in English, while conference abstracts and unpublished sources were excluded.

Results: Increased levels of p-syn have been observed in various samples from MSA patients, such as red blood cells, cerebrospinal fluid, oral mucosal cells, skin, and colon biopsies, highlighting their diagnostic potential. The α-Syn RT-QuIC assay has shown sensitivity in diagnosing MSA and tracking its progression. Meta-analyses and multicenter investigations have confirmed the diagnostic value of p-syn in cerebrospinal fluid, demonstrating high specificity and sensitivity in distinguishing MSA from other neurodegenerative diseases. Moreover, combining p-syn with other biomarkers has further improved the diagnostic accuracy of MSA.

Conclusion: The p-syn stands out as a promising biomarker for MSA. It is found in oligodendrocytes and shows a correlation with disease severity and progression. However, further research and validation studies are necessary to establish p-syn as a reliable biomarker for MSA. If proven, p-syn could significantly contribute to early diagnosis, disease monitoring, and assessing treatment response.

Citing Articles

The potential of phosphorylated α-synuclein as a biomarker for the diagnosis and monitoring of multiple system atrophy.

Abdul-Rahman T, Herrera-Calderon R, Ahluwalia A, Wireko A, Ferreira T, Tan J CNS Neurosci Ther. 2024; 30(4):e14678.

PMID: 38572788 PMC: 10993367. DOI: 10.1111/cns.14678.

References

Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen P, Habenstein B . Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013; 4:2575. PMC: 3826637. DOI: 10.1038/ncomms3575. View

Bernis M, Babila J, Breid S, Wusten K, Wullner U, Tamguney G . Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein. Acta Neuropathol Commun. 2015; 3:75. PMC: 4660655. DOI: 10.1186/s40478-015-0254-7. View

Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg M . alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol. 2002; 4(2):160-4. DOI: 10.1038/ncb748. View

Stewart T, Sossi V, Aasly J, Wszolek Z, Uitti R, Hasegawa K . Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun. 2015; 3:7. PMC: 4362824. DOI: 10.1186/s40478-015-0185-3. View

Martinez-Valbuena I, Visanji N, Olszewska D, Sousa M, Bhakta P, Vasilevskaya A . Combining Skin α-Synuclein Real-Time Quaking-Induced Conversion and Circulating Neurofilament Light Chain to Distinguish Multiple System Atrophy and Parkinson's Disease. Mov Disord. 2022; 37(3):648-650. DOI: 10.1002/mds.28912. View

Ahmed Z, Asi Y, Sailer A, Lees A, Houlden H, Revesz T . The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol Appl Neurobiol. 2011; 38(1):4-24. DOI: 10.1111/j.1365-2990.2011.01234.x. View

Bendor J, Logan T, Edwards R . The function of α-synuclein. Neuron. 2013; 79(6):1044-66. PMC: 3866954. DOI: 10.1016/j.neuron.2013.09.004. View

Vanacore N, Bonifati V, Fabbrini G, Colosimo C, De Michele G, Marconi R . Case-control study of multiple system atrophy. Mov Disord. 2004; 20(2):158-63. DOI: 10.1002/mds.20303. View

Miglis M, Muppidi S . Synuclein in red blood cells: a potential biomarker for multiple system atrophy, and other updates on recent autonomic research. Clin Auton Res. 2020; 30(2):107-109. DOI: 10.1007/s10286-020-00680-7. View

10.

Magalhaes P, Lashuel H . Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson's disease and other synucleinopathies. NPJ Parkinsons Dis. 2022; 8(1):93. PMC: 9307631. DOI: 10.1038/s41531-022-00357-0. View

11.

Xie D, Feng L, Huang H, Zhao Q, Ning P, Shen Q . Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Relative to Parkinson's Disease: A Meta-Analysis. Behav Neurol. 2021; 2021:5559383. PMC: 8188602. DOI: 10.1155/2021/5559383. View

12.

Bouwmans A, Vlaar A, Srulijes K, Mess W, Weber W . Transcranial sonography for the discrimination of idiopathic Parkinson's disease from the atypical parkinsonian syndromes. Int Rev Neurobiol. 2010; 90:121-46. DOI: 10.1016/S0074-7742(10)90009-3. View

13.

Guo Y, Shen X, Huang S, Chen S, Wang H, Zhang W . Head-to-head comparison of 6 plasma biomarkers in early multiple system atrophy. NPJ Parkinsons Dis. 2023; 9(1):40. PMC: 10017699. DOI: 10.1038/s41531-023-00481-5. View

14.

Jellinger K . Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1. J Alzheimers Dis. 2017; 62(3):1141-1179. PMC: 5870010. DOI: 10.3233/JAD-170397. View

15.

Paleologou K, Oueslati A, Shakked G, Rospigliosi C, Kim H, Lamberto G . Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein oligomerization, and influences synuclein-membrane interactions. J Neurosci. 2010; 30(9):3184-98. PMC: 2947449. DOI: 10.1523/JNEUROSCI.5922-09.2010. View

16.

Bjornsdottir A, Gudmundsson G, Blondal H, Olafsson E . Incidence and prevalence of multiple system atrophy: a nationwide study in Iceland. J Neurol Neurosurg Psychiatry. 2012; 84(2):136-40. DOI: 10.1136/jnnp-2012-302500. View

17.

Watanabe H, Shima S, Mizutani Y, Ueda A, Ito M . Multiple System Atrophy: Advances in Diagnosis and Therapy. J Mov Disord. 2022; 16(1):13-21. PMC: 9978260. DOI: 10.14802/jmd.22082. View

18.

Desplats P, Lee H, Bae E, Patrick C, Rockenstein E, Crews L . Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A. 2009; 106(31):13010-5. PMC: 2722313. DOI: 10.1073/pnas.0903691106. View

19.

Zhang J, Li X, Li J . The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases. Front Neurosci. 2019; 13:381. PMC: 6482271. DOI: 10.3389/fnins.2019.00381. View

20.

Gilman S, Wenning G, Low P, Brooks D, Mathias C, Trojanowski J . Second consensus statement on the diagnosis of multiple system atrophy. Neurology. 2008; 71(9):670-6. PMC: 2676993. DOI: 10.1212/01.wnl.0000324625.00404.15. View